A recent press release from Athera Biotechnologies describes how Olink panels were used to measure 251 proteins in a longitudinal study of patients undergoing vascular leg surgery and treated with the fully human anti-phosphorylcholine antibody, PC-mAb. 65 of the proteins measured were significantly increased following surgery, and 18 proteins were differentially affected by treatment with PC-mAb. The data was presented at the 19th Swedish Cardiovascular Spring meeting, and the authors concluded that this type of proteomics analysis could to be used to study treatment effects of PC-mAb in future clinical studies.
See the full press release here.